News

December 12, 2019December 12, 2019

Defects in Molecular Chaperones May Help Drive Lewy Body Formation in Parkinson’s, Study Finds

News

Defects in chaperone proteins that interact with alpha-synuclein and work as a type of “molecular bodyguard” may help drive the formation of Lewy bodies, which are a hallmark of ... Read more

December 12, 2019December 12, 2019

3D Structure of Brain Alpha-Synuclein More Heterogeneous Than Previously Thought, New Study Reports

News

Clumps, or aggregates of alpha-synuclein protein in the brain, a hallmark of Parkinon’s disease, are more heterogeneous than previously thought, according to a new study. Moreover, the protein’s 3D-structure ... Read more

December 11, 2019December 11, 2019

Alpha-synuclein Blood Levels May Be Biomarker for Parkinson’s with Motor Symptoms

News

Measuring the levels of alpha-synuclein in red blood cells can reliably distinguish people with Parkinson’s disease and evident motor symptoms from healthy individuals, and could serve as a diagnostic biomarker, a ... Read more

December 11, 2019December 11, 2019

First DUB Enzymes Identified by Partnership as Potential Therapeutic Targets for Parkinson’s and Alzheimer’s

News

Mission Therapeutics and AbbVie have identified several molecules, called deubiquitylating enzymes, or DUBs, that may be potential therapeutic targets to treat Parkinson’s and Alzheimer’s diseases. This comes after the ... Read more

December 10, 2019December 10, 2019

Cerevance’s Phase 2 Trial Recruiting Patients to Test Oral CVN424 Therapy for Motor Symptoms

News

Cerevance has initiated a Phase 2 clinical trial to evaluate the safety and efficacy of its oral investigational therapy CVN424 for treating Parkinson’s disease motor symptoms. CVN424 is small ... Read more

December 10, 2019December 10, 2019

Novartis’ Tasigna Fails to Show Clinically Meaningful Benefits in Parkinson’s, Phase 2 Trial Shows

News

Tasigna (nilotinib), an approved leukemia medication being tested as a repurposed treatment for Parkinson’s disease, failed to show any clinically meaningful benefits in a Phase 2 trial, the study’s steering ... Read more

December 9, 2019December 9, 2019

Phase 2 Study to Evaluate Possible Oral Treatment for Mild Cognitive Impairment in Parkinson’s

News

Aptinyx will soon open a Phase 2 clinical study of NYX-458, a potential oral treatment of mild cognitive impairment (MCI) associated with Parkinson’s disease (PD). Although the main features ... Read more

December 9, 2019December 9, 2019

Falls and Poor Bone Health Top Reasons for High Fracture Risk in Parkinson’s, Study Says

News

People with Parkinson’s disease are at elevated risk of hip and non-vertebral fractures mostly because of the balance problems inherent to the disease and poorer bone health, a review ... Read more

December 6, 2019

Deep Brain Stimulation May Impair Swimming Ability and Increase Risk of Drowning, Case Studies Suggest

News

Patients who undergo deep brain stimulation to treat Parkinson’s disease may lose their ability to swim, even if their motor symptoms improve after the treatment or if they were ... Read more

December 6, 2019December 6, 2019

Dosing Begins in Phase 2 Trial of CNM-Au8, Potential Therapy for Dopaminergic Neurons

News

A pilot Phase 2 study evaluating CNM-Au8, an investigational Parkinson’s treatment aiming to protect nerve cells, has started dosing patients, the therapy’s developer, Clene Nanomedicine, announced. The open-label REPAIR-PD (NCT03815916) clinical trial ... Read more

Pin It on Pinterest